Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
04:00:00 2026-08-17 pm EDT
|
5-day change | 1st Jan Change | ||
| 52.05 USD | -0.89% |
|
-1.64% | +18.16% |
| Aug. 10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| Aug. 10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 6,396 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 42.34% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 6,079 | 5,991 | 6,026 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 42.38% | -1.44% | 0.58% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -16x | -20.3x | -33.1x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 23.9x | 21.4x | 23.7x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 12.33x | 1x | 0.9x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 1,111x | 43.2x | 18.2x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 1,056x | 40.5x | 17.2x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -14.2x | -20.3x | -62.5x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -13.9x | -17.2x | -30.5x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -18.1x | -28x | -70.5x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.51% | -3.57% | -1.42% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.247 | -2.561 | -1.571 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 5.756 | 147.9 | 350.7 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -429 | -295.2 | -96.48 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -437.6 | -347.3 | -197.9 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -425.3 | -362.1 | -217.8 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -317.2 | -404.9 | -369.9 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 52.05 | 52.05 | 52.05 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 121,785 | - | - |
| Announcement Date | 3/7/22 | 3/7/23 | 3/19/24 | 2/27/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -16.17x | 1056.09x | -14.17x | -.--% | 6.4B | |
| 20.97x | 7.34x | 14.96x | 1.41% | 70.07B | |
| 30.34x | 7.64x | 23.38x | 0.05% | 52.87B | |
| -78.21x | 14.61x | -74.55x | -.--% | 27.02B | |
| 29.96x | 5.86x | 15.52x | -.--% | 23.61B | |
| -14.6x | 5.15x | -6.71x | -.--% | 23.38B | |
| 56.69x | 21.05x | 42.62x | 0.06% | 19.43B | |
| 25.59x | 4.85x | 16.27x | -.--% | 18.75B | |
| -802.92x | 37.67x | -14929.22x | -.--% | 15.85B | |
| 15.89x | 4.68x | 10.93x | -.--% | 12.7B | |
| Average | -73.25x | 116.49x | -1,490.10x | 0.15% | 27.01B | |
| Weighted average by Cap. | -36.00x | 35.11x | -870.22x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
